Summary The National Institute on Aging Interventions Testing Program (ITP) evaluates
agents hypothesized to increase healthy lifespan in genetically heterogeneous mice. Each …

Background Metformin is a commonly used drug for the treatment of diabetes. Accumulating
evidence suggests that it exerts anti-tumor effects in many cancers, including multiple …

In the past decade, studies of the human tumour suppressor LKB1 have uncovered a novel
signalling pathway that links cell metabolism to growth control and cell polarity. LKB1 …

Background: Metformin, a first line antihyperglycemic medication, is an AMPK activator and
has been hypothesized to act as a geroprotective agent. Studies on its association with …

Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest
experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many …

Metformin is everywhere. Originally introduced in clinical practice as an antidiabetic agent,
its role as a therapeutic agent is expanding to include treatment of prediabetes mellitus …

The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in∼ 20% of non-
small cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy …

Cancer therapy has long relied on the rapid proliferation of tumour cells for effective
treatment. However, the lack of specificity in this approach often leads to undesirable side …

When energy supply is low, organisms respond by slowing aging and increasing resistance
to diverse age-related pathologies. Targeting the mechanisms underpinning this response …

Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy
metabolism and growth. There is now considerable evidence that these hormones and the …